https://www.selleckchem.com/pr....oducts/chk2-inhibito
The prognosis of COVID-19 patients with cardiac involvement is unfavorable and it remains unknown which patients are at risk. The virus enters cells via its receptor angiotensin-converting enzyme 2 (ACE2). Myocardial ACE2 expression is increased in structural heart disease (SHD). We, therefore, aimed to analyze correlations between structural heart disease and cardiac SARS-CoV-2 manifestation. The clinical course of COVID-19 in patients with structural heart disease was assessed in a prospective cohort of 152 patients.
Like
Comment
Share
